ライフサイエンスコーパス: reoperation

1 re and Complications, Cancer Management, and Reoperation.

2 and potentially identify cases that require reoperation.

3 eater than 32, combined transplantation, and reoperation.

4 90-day mortality, serious complications, and reoperation.

5 cting adverse events including mortality and reoperation.

6 l complications were reported except for one reoperation.

7 s was associated with a 33% lower risk for a reoperation.

8 01) after PME, including SSI/SSO, SSOPI, and reoperation.

9 ence of hiatal hernia or wrap migration, and reoperation.

10 ntly induces a V-pattern esotropia requiring reoperation.

11 ong-term survival and freedom from autograft reoperation.

12 se disparate studies, 27 cases (5%) required reoperation.

13 ction develops later and can persist despite reoperation.

14 Two eyes received surgical revision, and 1 a reoperation.

15 ty, cause of death, relapse, recurrence, and reoperation.

16 re and Complications, Cancer Management, and Reoperation.

17 ypovitaminosis B(12) and 2 patients required reoperation.

18 eak occurred in 16% of patients, 2% required reoperation.

19 <5 mmHg at 2 consecutive visits, or glaucoma reoperation.

20 developed carinate overcorrection requiring reoperation.

21 stomotic leakage requiring reintervention or reoperation.

22 nt stent placement versus those who required reoperation.

23 n, wound infection, bleeding, amputation, or reoperation.

24 f long-term device-related complications and reoperations.

25 affect long-term morbidity and often require reoperations.

26 sing Fisher exact test for complications and reoperations.

27 mus surgeries, but the accuracy decreases in reoperations.

28 r malfunction), driven by a reduced need for reoperations.

29 r failure, interventions, complications, and reoperations.

30 224 million (47.6%) of the payments were for reoperations.

31 success), interventions, complications, and reoperations.

32 s for the index operation and any subsequent reoperations.

33 demonstrated less pump thrombosis requiring reoperation (0 versus 36 points, P<0.001) or medically m

34 hemorrhage (0.85% vs 1.27%, P = 0.005), and reoperation (0.24% vs 0.92%, P < 0.0001).

35 4% vs 1.7%; P < 0.001), complication-related reoperations (1.1% vs 0.8%; P = 0.008), pain at rest (5.

36 8% vs 3.3%; P = 0.029), complication-related reoperations (1.2% vs 0.9%; P = 0.019), pain at rest (5%

37 rcutaneous drainage (12% vs 12%, P = 0.809), reoperation (11% vs 13%, P = 0.329), and hospital stay (

38 orbidity (18.7% vs 25.3%; P = 0.83), rate of reoperation (16.6% vs 21.0%; P = 0.22), length of hospit

39 urrent laryngeal nerve palsy (9.5% vs 0.5%), reoperations (18.6% vs 11.0%), 90-day mortality (7.1% vs

40 complications (18% versus 24%, P=0.439), or reoperation (21% versus 24%, P=0.650).

41 er rates of SSOPI (46% vs 24%, P = 0.04) and reoperation (21% vs 6%, P = 0.03) were seen after PME.

42 gency room (ER) visits at 30 or 90 days (30D reoperation 3.6% vs 3.7%; P = 0.83, 90D reoperation 3.8%

43 (30D reoperation 3.6% vs 3.7%; P = 0.83, 90D reoperation 3.8% vs 3.9%; P = 0.84) (30D readmission 9.9

44 sted rates of DSM (9.0% vs 7.1%; P < 0.001), reoperation (3.6% vs 2.7%; P < 0.001), and readmission (

45 median LOS (equivalent at 7 days, P = 0.09), reoperation (3.6% vs 4.0%, P = 0.74), or re-admission to

46 uired readmission (6.1%), of whom 6 required reoperation (3.8%).

47 notable with regards to bleed events, 30-day reoperation, 30-day readmission, operative time, and hos

48 tive complications (0.6% vs. 0%, p = 0.498), reoperation (4.1% vs. 3.0%, p = 0.758) or urinary incont

49 geal nerve injury (13.4% vs 6.6%), unplanned reoperations (4.4% vs 1.3%), and longer hospital stay (3

50 A total of 725 patients (17.6%) underwent a reoperation: 593 were reexcisions (14.4%) and 132 were m

51 Results: Using follow-up (93%) or reoperation (7%) as the reference standard, PET combined

52 For each eye that underwent reoperation, a control was time-matched within 1 month.

53 n with IBC (454 of 3391 [13.4%]) underwent a reoperation (adjusted odds ratio, 3.82; 95% CI, 3.19-4.5

54 If surgery has failed reoperation after careful re-evaluation may be a reasona

55 The number of reoperations after failed gastric banding rapidly increa

56 90-day mortality, serious complications, and reoperation (all P < 0.0001).

57 ks managed with stents to those treated with reoperation alone.

58 tructions, and is the most common reason for reoperation among augmentations.

59 ow-up, 4636 patients (18.5%) underwent 17539 reoperations (an average of 3.8 procedures/patient).

60 ty, conversion rate, grade III/IV morbidity, reoperation, anastomotic leak, nodes retrieved, involved

61 Age under 2 years was associated with higher reoperation and abnormal binocularity rates (P < .001).

62 Early reoperation and biliary/vascular complication rates were

63 ty, overall morbidity, development of ileus, reoperation and Clostridium difficile infection.

64 discovered gallbladder cancer who underwent reoperation and had available data on the date of their

65 n be effective; however, it does not prevent reoperation and is associated with an increased likeliho

66 e peeling was associated with lower rates of reoperation and RD.

67 ween 2008 and 2016, and to identify cases of reoperation and subsequent retinal detachment within 1 y

68 as also associated with reduced incidence of reoperations and valve-related complications.

69 cidence of end-organ dysfunction, mortality, reoperation, and hospital readmission, with estimated po

70 percutaneous drainage procedures, unplanned reoperation, and hospital revisits).

71 es of severe complication, any complication, reoperation, and percutaneous drainage (all P < 0.05).

72 nic Health Evaluation II (APACHE II) scores, reoperation, and postoperative bleeding.

73 omes included 30-day rates of complications, reoperation, and readmission in urgent cases compared wi

74 y mitral repair rates, but also freedom from reoperation, and survival.

75 provement of the condition, the high rate of reoperation, and the long-term positive outcomes of defe

76 death or serious morbidity (DSM), unplanned reoperation, and unplanned readmission in concurrent ver

77 act removal, the incidence of complications, reoperations, and glaucoma was low when surgery was perf

78 he sleeve procedure is associated with fewer reoperations, and the bypass procedure may lead to more

79 yses of the rate of recurrent infections and reoperations, and time trends in surgical treatment.

80 rt failure, paraplegia, dyspnea at rest, and reoperation are associated with the highest risk of post

81 of the patients who received stents required reoperation as part of their care pathway.

82 dhesions are particularly problematic during reoperations, as surgeons must release the adhesions fro

83 Freedom from autograft reoperation at 10 years was 82% (95% CI: 64.1% to 91.5%)

84 ) were discovered incidentally and underwent reoperation at 3 different time intervals from the date

85 ithin 180 days and over 20% of eyes required reoperation at any time postoperatively with a mean foll

86 ain primary endpoint was number of unplanned reoperations at 24 months, and safety expressed as the i

87 visits after the first postoperative month, reoperation because of uncontrolled IOP or disease progr

88 Among IHT patients, 51% underwent reoperation before transfer and 34.9% experienced hemorr

89 Patients who underwent reoperation between 4 and 8 weeks had the longest median

90 , but no difference was found in the type of reoperation between patients with DCIS and those with IB

91 Reoperation by 3 years occurred in 9 participants (10%)

92 ficant difference in rates of readmission or reoperation by approach.

93 ation was found in the data; 90-day rates of reoperations by surgeon ranged from 0% to 100%.

94 Discrimination of the SRC was lowest for reoperation (C-index, 0.533) and highest for discharge t

95 IME trial was associated with a reduction in reoperations, Clavien-Dindo grade > 1 complications, and

96 ostoperative ileus, sepsis, readmission, and reoperation compared with patients who received neither

97 ong-term survival and freedom from autograft reoperation compared with primary Ross procedure.

98 ed a trend of more overall complications and reoperations (difference 0.16, 95% CI, -0.01 to 0.32, P

99 Primary outcome measures were reoperation due to hernia recurrence and postoperative 3

100 luding congestive heart failure, paraplegia, reoperation, dyspnea at rest, nongastric band surgery, a

101 Reoperation for bar displacement occurred in 1.8%, hemot

102 ys), transient ischemic attack in 1 patient, reoperation for bleeding in 2 patients, and median lengt

103 th increased unplanned cardiac operation and reoperation for bleeding.

104 consecutive follow-up visits after 3 months, reoperation for glaucoma or a complication, or loss of l

105 educed >/=20% from baseline, IOP >5 mmHg, no reoperation for glaucoma, no loss of light-perception vi

106 an 20% from baseline, IOP of 5 mmHg or less, reoperation for glaucoma, or loss of light perception vi

107 an 20% from baseline, IOP of 5 mmHg or less, reoperation for glaucoma, or loss of light perception vi

108 llow-up visits >3 months after implantation, reoperation for glaucoma, or loss of light perception vi

109 IOP) >21 mmHg or a reduction <20%, hypotony, reoperation for glaucoma, or loss of light perception.

110 and thoracic surgeons were at higher risk of reoperation for noncomplication causes (relative risk fo

111 igh rate of device-related complications and reoperation for other causes after ICD implantation.

112 Four percent of patients required reoperation for overcorrection (mean 2.7 years) and 5% d

113 the rates of death or disabling stroke, but reoperation for pump malfunction was less frequent in th

114 pump, primarily because of the lower rate of reoperation for pump malfunction.

115 requiring reoperation or hospitalization and reoperation for reasons other than complications, and to

116 ain Outcomes and Measures: Five-year risk of reoperation for recurrence and 5-year risk of all mesh-r

117 ere not associated with an increased risk of reoperation for recurrence compared with heavyweight mes

118 repair was associated with a higher risk of reoperation for recurrence over 5 years compared with op

119 The 10-year cumulative incidence of reoperation for recurrence was 14.1% (95% CI 12.3%-16.0%

120 t the time of repair was not associated with reoperation for recurrence, while a subsequent pregnancy

121 as were associated with an increased risk of reoperation for recurrence.

122 Primary endpoint was reoperation for recurrence.

123 The primary outcome was rate of reoperation for recurrent ERM according to whether or no

124 f the patients are off PPIs, and 16% require reoperation for recurrent GERD and/or dysphagia.

125 ary (18)F-FET PET is relevant in cases where reoperation for residual tumor is considered.

126 mplications for the majority of defects, and reoperation for valvar problems is common.

127 lysis showed that the adjusted odds ratio of reoperation for women having 1 previous cesarean deliver

128 The rate of reoperations for bleeding tended to be higher in the NTT

129 ient recurrent laryngeal nerve palsy (RLNP), reoperations for bleeding, inadvertently removed parathy

130 In this sample, reoperations for macular hole were performed at low rate

131 g long-term device-related complications and reoperations for noncomplication causes.

132 6.4%; other specialists, 15.2%; P<0.001) and reoperations for reasons other than complications (elect

133 quiring reoperations or hospitalizations and reoperations for reasons other than complications.

134 us adverse event, with the most common being reoperations (for reasons other than chronic pancreatiti

135 At 20 years, reoperation-free survival was 60.4% (95% confidence inte

136 interval from the initial cholecystectomy to reoperation: group A: less than 4 weeks; group B: 4 to 8

137 ents (mean age, 57.5; 76.2% women) requiring reoperation had lower rates of hypertension (64.9% vs 73

138 Laparoscopic lavage reduced the need for reoperations, had a similar safety profile to the Hartma

139 ant associations between low IOP and time to reoperation (hazard ratio [HR], 0.73; 95% CI, 0.32-1.68)

140 Key secondary outcomes were number of reoperations, hospital readmissions, total length of hos

141 lower rates of obstruction, hemorrhage, and reoperation; however, severe morbidity remained extremel

142 reased total and pulmonary complications and reoperations; however, benefits included increased propo

143 dures were associated with increased risk of reoperations (HR: 6.9; p = 0.003), and m-CVG procedures

144 = 42) and 93% (n = 14), respectively, due to reoperation in a small minority.

145 However, the risk of reoperation in patients with DCIS was 3 times higher tha

146 e-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve fail

147 cant differences in survival or freedom from reoperation in the unmatched cohort.

148 h node harvest, resection margin status, and reoperation incidence were assessed as performance-contr

149 However, 42.5% of the patients needed reoperation, including 10.6% for correction of protein m

150 006 and 2013 identifies gastric band-related reoperations, including device removal, device replaceme

151 the proportion of payments from Medicare for reoperations increased from 16.4% to 77.3% of their annu

152 higher rates of nerve injury and unexpected reoperations, indicating surgical complexity and provide

153 ion duration, additional use of painkillers, reoperation, infection, seroma, extended wound care, ext

154 tu (DCIS) and to examine whether the risk of reoperation is associated with DCIS or histologic type o

155 ere overall morbidity and mortality, rate of reoperation, length of hospital stay, and rate of stoma

156 ve wound infection, intra-abdominal abscess, reoperation, length of hospital stay, and readmission.

157 ogy results, complications, reinterventions, reoperations, length of stay, and mortality.

158 17.4 months) or late (group C: 22.4 months) reoperation (log-rank P = .03).

159 n in risk- and reliability-adjusted rates of reoperation (lower quartile average, 13.3%; upper quarti

160 erence in number of complications treated by reoperation (LSG, n = 9; LRYGB, n = 16, P = 0.15) or num

161 resection and stoma formation with risk for reoperations, morbidity, and mortality.

162 Among 1,820 participants, the risk of reoperation/mortality did not increase with greater lymp

163 The main study outcome was reoperation/mortality within 30 days of primary surgery.

164 node metastases did not increase the risk of reoperation/mortality.

165 ifferences in intraabdominal leak, unplanned reoperation, myocardial infarction, or infectious compli

166 Rate of device-related reoperation nationally and across individual hospital re

167 r hemorrhage or cardiac tamponade leading to reoperation occurred in 1.4% of the patients in the tran

168 Unplanned intraocular reoperation occurred in 28% of first enrolled eyes (incl

169 Recurrence requiring reoperation occurred in 3 primary surgical patients.

170 lications producing vision loss or requiring reoperation occurred with similar frequency after both s

171 20%), including glaucoma or GS and VAO, and reoperations occurred in a similar proportion to that of

172 Two 30-day reoperations occurred, both laparoscopic; p = 0.545.

173 To describe the rate of device-related reoperations occurring after laparoscopic gastric band s

174 The odds of reoperation of PPV +/- SB compared with SB only varies d

175 ted deaths was 12%, noncardiac deaths 21.3%, reoperation on the MV 4.6%, infective endocarditis 1.1%,

176 risk for ICD-related complications requiring reoperation or hospitalization and reoperation for reaso

177 nd 17% (13 of 77) in the R&R group underwent reoperation or met suboptimal surgical outcome criteria

178 st increases the risk of early postoperative reoperation or mortality.

179 Serious complications requiring reoperation or producing loss of 2 or more Snellen lines

180 -term device-related complications requiring reoperations or hospitalizations and reoperations for re

181 50 years with PPV +/- SB had a lower odds of reoperation (OR 0.73, 95% CI 0.63-0.84, P < .0001).

182 readmission (OR 0.96, 95% CI 0.93-0.99), and reoperation (OR 0.96, 95% CI 0.93-0.99), respectively.

183 08; 95% confidence interval [CI] 0.96-1.21), reoperation (OR 1.16; 95% CI 0.96-1.40), or readmission

184 d with PPV +/- SB exhibited a higher odds of reoperation (OR 1.46, 95% CI 1.14-1.88, P = .003) compar

185 PI (OR 1.5, 95% CI 1.05-2.14; P = 0.023) and reoperation (OR 2.2, 95% CI 1.13-4.10; P = 0.015) with P

186 0.001), open procedure (OR: 3.2; P < 0.001), reoperation (OR: 4.5; P < 0.001), and low hospital casel

187 neck dissections (OR: 3.10), and unexpected reoperations (OR = 3.55); all P values less than 0.01.

188 plications (OR, 1.50; 95% CI, 1.29 to 1.74), reoperations (OR, 1.74; 95% CI, 1.42 to 2.14), and lengt

189 complication [OR, 0.98 (95% CI, 0.76-1.3)], reoperation [OR, 0.65 (95% CI, 0.42-1.0)], readmission [

190 amount of lagophthalmos, cosmesis, exposure, reoperation, or complications, as well as prosthesis ret

191 ve wound infection, intra-abdominal abscess, reoperation, or readmission.

192 Ten percent and 5% underwent reoperation (P = 0.11).

193 wer postoperative complications (P < 0.001), reoperations (P < 0.001), infections (P = 0.007), genera

194 serious complications (P < 0.001) or perform reoperations (P < 0.001).

195 , APACHE II scores (P = 0.256), incidence of reoperations (P = 1.000), or postoperative bleeding (P =

196 ong adolescents than among adults (19 vs. 10 reoperations per 500 person-years, P = 0.003).

197 measure was aseptic revision, defined as any reoperation performed after the index procedure involvin

198 ious cesarean delivery increases the risk of reoperation, perioperative and postoperative complicatio

199 Reoperation, perioperative and postoperative complicatio

200 ere 30-day mortality, end-organ dysfunction, reoperation, prolonged hospitalization, nonroutine disch

201 as been associated with an increased risk of reoperation, prolonged hospitalization, readmission, and

202 renal failure, deep sternal wound infection, reoperation, prolonged ventilation).

203 The reported rates of reoperation range from 4% to 60% in short-term studies;

204 s (7.46% vs 3.69%, P < 0.001), as was 30-day reoperation rate (3.25% vs 1.26%, P < 0.001).

205 sidual grade III HD (15% vs 5%) and a higher reoperation rate (8% vs 4%).

206 Reoperation rate after wire-guided BCS in patients with

207 To determine the reoperation rate after wire-guided BCS in patients with

208 A lower reoperation rate after wire-guided BCS was found in this

209 mpact of the absence of band fixation on the reoperation rate and to identify other risk factors for

210 tion from 20.9% to 15.2% (P = .004), and for reoperation rate at 55 cases, with a reduction from 12.6

211 However, a valid reoperation rate for this procedure needs to be establis

212 nonpalpable breast lesions may decrease the reoperation rate in breast-conserving surgery (BCS) comp

213 ble sutures were not associated with a lower reoperation rate in children.

214 At 7 years, reoperation rate is 11.7% for primary augmentation, and

215 ptable with no early or late deaths, 3-month reoperation rate of 3.1%, and overall complication rate

216 The overall reoperation rate was 12.2% for SB and 11.6% for PPV +/-

217 Overall complication rate was 56% and reoperation rate was 15% with no difference in complicat

218 igh IOP, and the cumulative de novo glaucoma reoperation rate was 18% in the Ahmed group and 11% in t

219 The overall reoperation rate was 32%.

220 ative bleb needling cases were excluded, the reoperation rate was 6.5% (57/881) within 180 days and 1

221 The reoperation rate was 7.4% for fixed-suture surgeries, 9.

222 The reoperation rate was significantly lower among patients

223 The reoperation rate within 180 days was 9.5% (84/881) and a

224 The primary outcome was the reoperation rate within 2 years since first surgery.

225 ths of age (AE rate, 21% vs. 25% [P = 0.60]; reoperation rate, 13% vs. 16% [P = 1.00]).

226 0-day morbidity (17.1% vs 15.7%, P = 0.823), reoperation rate, and readmission rate between the 2 gro

227 ase in total and pulmonary complications and reoperation rate.

228 Outcomes and reoperation rates in infants with unilateral persistent

229 Reoperation rates tended to be higher with adjustable su

230 val is associated with significantly reduced reoperation rates within 1 year.

231 is to analyze the preoperative measurements, reoperation rates, and complications after surgery in un

232 prism diopters [PDs]; minimal <=10 PD), and reoperation rates.

233 time is a risk factor associated with higher reoperation rates.

234 eved better results with significantly lower reoperation rates.

235 ons and four (50%) measured 30 day unplanned reoperation rates.

236 matic reviews shows that difficulties during reoperations, rather than small bowel obstructions, acco

237 omes, including mortality, any complication, reoperation, readmission, and length of stay.

238 urgery is not associated with an increase in reoperation, readmission, ER visits, or unanticipated re

239 omy hemorrhage (PPH), bile leak, blood loss, reoperation, readmission, oncologic outcomes (R0-resecti

240 , any overlap did not predict an increase in reoperation, readmission, or emergency room (ER) visits

241 ak, pneumonia, nasogastric tube reinsertion, reoperation, readmission, or mortality in the randomized

242 mplications, LOS, POPF, DGE, PPH, bile leak, reoperation, readmission, or oncologic outcomes between

243 ative imaging, percutaneous drain placement, reoperation, readmission, or quality of life scores.

244 perative complications, complication-related reoperations, recurrences, and pain on exertion was foun

245 l site infection, sepsis, pneumonia, stroke, reoperation, reintervention, early extubation, and readm

246 ment of bariatric complications and rates of reoperation remain unknown.

247 10 to 1.17; p < 0.001); a steady decrease in reoperation risk until 25 total mitral operations annual

248 and pelviperineal complication necessitating reoperation (RR 1.06; 95% CI 0.80-1.42) as well.

249 se in major bleeding complications requiring reoperation (RR, 0.57; 95% CI, 0.39-0.84; I(2) = 32%; 10

250 Adhesiolysis during reoperations seems to impact adhesion-related morbidity

251 bidity, unplanned readmission, and unplanned reoperation, separately, while adjusting for patient- an

252 We compared long-term mortality and rates of reoperation, stroke, and bleeding between inverse-probab

253 ioprosthetic aortic valve replacement (AVR), reoperation to relieve severe prosthetic aortic stenosis

254 The need for reoperation to repair RRD within 90 days was independent

255 vival at 2 years free of disabling stroke or reoperation to replace or remove a malfunctioning device

256 pect to survival free of disabling stroke or reoperation to replace or remove a malfunctioning device

257 mained alive and free of disabling stroke or reoperation to replace or remove a malfunctioning device

258 more severe disability) or survival free of reoperation to replace or remove the device at 6 months

259 oint (survival free of a disabling stroke or reoperation to replace the pump for malfunction), driven

260 though the accuracy decreased when comparing reoperations to primary surgeries for the medial (79% to

261 tis, return to baseline health, readmission, reoperation, unplanned appendectomy, adverse events rela

262 Groups were similar in the incidence of reoperation, vascular thrombosis, posttransplant lymphop

263 Low IOP after trabeculectomy, reoperation, vision loss, and surgical failure.

264 erative outcomes that were examined included reoperation, vision loss, and surgical failure.

265 The cumulative rate of reoperation was 14% in the fusion group and 34% in the d

266 stomotic leakage requiring reintervention or reoperation was 23.3% after McKeown TMIE versus 12.4% af

267 .e., MR >/=2) was 13.3%, incidence of mitral reoperation was 6.9%, and overall mortality was 44.0%.

268 Freedom from reoperation was 69% at 15 years and 63% at 20 years.

269 ergoing gastric band surgery, device-related reoperation was common, costly, and varied widely across

270 The last of the 6 who required reoperation was in the elevator weakening group, and req

271 Reoperation was performed for 6 of 22 patients.

272 Reoperation was performed in 19 PVP operated patients (1

273 aracteristics and risk factors for death and reoperation was performed.

274 The incidence of reoperation was significantly higher among recipients of

275 The risk of reoperation was significantly increased in patients with

276 MV reoperation was uncommon after MV repair, but there was

277 The rate of abdominal reoperations was significantly higher among adolescents

278 For vertical surgeries, predictors of reoperation were adjustable-suture use (OR 2.51, P = .10

279 ith structural valve deterioration requiring reoperation were assumed to undergo a valve-in-valve TAV

280 complications and complications resulting in reoperation were higher in the Baerveldt Glaucoma Implan

281 Rates of reoperation were highest in women aged 20 to 49 years (3

282 The odds of reoperation were lower in women (OR 0.91, 95% CI 0.85, 0

283 The rates of reoperation were risk adjusted using a multivariable log

284 The rates for definite reoperations were 1.3% (1.2% after ILM peeling and 1.8%

285 Neither AEs nor intraocular reoperations were more common for children with surgery

286 er operating times were at a higher risk for reoperation when performed by supervised trainees [57 to

287 erious morbidity, percutaneous drainage, and reoperation while achieving a length of stay equal to or

288 1.4% (n = 6) needed reoperation while the other 1.0% (n = 4) could be treate

289 interval from the initial cholecystectomy to reoperation with overall survival.

290 tmann group (25 of 40; 62.5%) had at least 1 reoperation within 12 months (relative risk reduction, 5

291 e PPV +/- SB group exhibited a lower odds of reoperation within 12 months compared with SB only (OR 0

292 The primary outcome was the odds of reoperation within 12 months.

293 In total, 388 women (5.0%) had a reoperation within 30 days after a hysterectomy.

294 ve heart failure, myocardial infarction, and reoperation within 30 days of surgery.

295 thalmitis, postoperative retinal detachment, reoperation within 30 days, dementia, anxiety disorder,

296 Nearly 1 in 4 women underwent a reoperation within 90 days of BCS across New York State

297 Mitral repair rates, mitral reoperations within 12 months of repair, and survival we

298 The most common reoperations within 180 days were bleb revision (32.1%)

299 e eye laterality was not coded) macular hole reoperations within 2, 3, and 12 months were queried.

300 f >=2 octaves, at any masked examination; or reoperation without meeting any of these criteria.